Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083114 | 0.87 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5083273 | 0.84 | ALDH1A1 (0.67) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10510514 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5086550 | 0.83 | DPP4 (0.48) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9684719 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL11123405 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5084361 | 0.80 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5080694 | 0.79 | TOP1 (0.59) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5083995 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5086541 | 0.78 | ALDH1A1 (0.65) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0447484-A1 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-25 | — | — | EP | claimed |
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-5385906-A | Treating gramnegative and grampositive bacterial infections | THE UPJOHN COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| US-5262417-A | Antibacterial quinolone compounds | THE UPJOHN COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0447484-A1 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KDM4E 3242/4885ALDH1A1 2348/4885LMNA 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.